Popular terms

[SEARCH]

Autoimmune Disease topics
Autoimmune Disease
Immune Disease
Autoimmune
Autoimmune Diseases
Immune Diseases
Transplant
Infectious Disease
Infectious
Inflammatory Disease
Antagonist
Rheumatoid Arthritis
Proliferative
Nucleotide
Antibodies
Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Disease patents



      
           
This page is updated frequently with new Autoimmune Disease-related patent applications. Subscribe to the Autoimmune Disease RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune Disease RSS RSS



Date/App# patent app List of recent Autoimmune Disease-related patents
07/23/15
20150204871 
 Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases patent thumbnailAutomated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases
A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Inc.


07/23/15
20150204867 
 Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases patent thumbnailAutomated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases
A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Inc.


07/23/15
20150203847 
 Chemical modifications of monomers and oligonucleotides with cycloaddition patent thumbnailChemical modifications of monomers and oligonucleotides with cycloaddition
In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

07/23/15
20150203820 
 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof patent thumbnailMesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
The present invention relates to methods of generating and expanding hitman embryonic stem eel! derived mesenchymal-like stem/siromal cells. These hes-mscs are characterized at least in part by the low level of expression of il-6.
Imstem Biotechnology, Inc.


07/23/15
20150203579 
 Human antibodies to pd-1 patent thumbnailHuman antibodies to pd-1
The present invention provides antibodies that bind to the t-cell co-inhibitor programmed death-1 (pd-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1.
Regeneron Pharmaceuticals, Inc.


07/23/15
20150203560 
 Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases patent thumbnailEngineered antibody-interferon fusion molecules for treatment of autoimmune diseases
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (ifn) molecule attached to an antibody (ab) which targets an antigen which is differentially expressed or up-regulated on activated t cells as compared to resting t cells, wherein the fusion molecule when contacted to an activated t cell results in induced apoptosis and programmed cell death or impairment of functions of said activated t cell..
Immungene Inc.


07/23/15
20150203556 
 Compositions and methods for modulation of il-20 family cytokine activity patent thumbnailCompositions and methods for modulation of il-20 family cytokine activity
Provided herein are compositions comprising one or more agents that inhibit or reduce the activity of il-20. Optionally, the agents further inhibit or reduce the activity of il-24.
The Uab Research Foundation


07/23/15
20150203455 
 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders patent thumbnailNovel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Wherein cy, r1, l1, r3, r4, r5, la, and ra are as defined herein. Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons..

07/23/15
20150202318 
 Aberrant cell-restricted immunoglobulins provided with a toxic moiety patent thumbnailAberrant cell-restricted immunoglobulins provided with a toxic moiety
Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.


07/23/15
20150202285 
 Compositions and methods for modulating immune responses patent thumbnailCompositions and methods for modulating immune responses
This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the nf-κb signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases..
The University Of Queensland


07/16/15
20150196511 

Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease


The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of il-17 and tnf-a, and promoting or increasing the activity of ifnr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease..
Catholic University Industry Academic Cooperation Foundation


07/09/15
20150191699 

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof


The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc derived cells and cell lineages “t-msc-dl” are also described.
Imstem Biotechnology, Inc.


07/09/15
20150191546 

Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease


The specification describes the sequences for antibodies that recognize the hla-a2-restricted peptide pr-1 in the context of hla presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided..
Board Of Regents, The University Of Texas System


07/09/15
20150191520 

Complement split product c4d for the treatment of inflammatory conditions


The present invention relates to a pharmaceutical composition comprising complement split product c4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The c4d to be used may be a multimer.
Medizinische Universität Wien


07/09/15
20150191503 

Organic compounds


This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.. .
Callaghan Innovation Research Limited


07/09/15
20150191466 

Tropomyosin-related kinase (trk) inhibitors


Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation


07/09/15
20150191464 

Heteroaryl substituted nicotinamide compounds


Or salts thereof, wherein: het is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1h-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with ra and rb; and r1 and r2 are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.

07/09/15
20150191417 

Anti-proliferative compounds and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject.
The General Hospital Corporation D/b/a Massachusetts General Hospital


07/02/15
20150183856 

Novel monoclonal antibody binding specifically to dll4 and use thereof


The present invention relates to a novel monoclonal antibody that binds specifically to delta-like ligand (dll4), and more particularly to a monoclonal antibody that binds specifically to human delta-like ligand 4 to effectively inhibit the interaction between delta-like ligand 4 and notch receptor, a polynucleotide encoding the monoclonal antibody, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the monoclonal antibody, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, a composition for diagnosing cancer comprising the monoclonal antibody, a method for diagnosing cancer using the monoclonal antibody, and a pharmaceutical composition for preventing or treating autoimmune disease comprising the monoclonal antibody.. .
Hanwha Chemical Corporattion


07/02/15
20150183775 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


07/02/15
20150182566 

Lactic acid bacterium-containing preparation


An object of the present invention is to provide a useful composition that contains a highly safe lactic acid bacterium or a component derived from this lactic acid bacterium. The present invention relates to a composition comprising at least one lactic acid bacterium selected from the group consisting of lactobacillus delbrueckii subsp.
Kaneka Corporation


07/02/15
20150182539 

Pregnancy hormone combination for treatment of autoimmune diseases


The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.. .
The Regents Of The University Of California


06/25/15
20150175979 

Ptprs and proteoglycans in autoimmune disease


Provided herein, inter alia, are ptprs de-clustering agents and compositions and kits comprising the agents. Provided are methods of modulating extracellular matrix or decreasing fibroblast activity in a subject.
La Jolla Institute For Allergy And Immunology


06/25/15
20150174178 

Method and system for prevention and treatment of allergic and inflammatory diseases


A method and system for exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..

06/25/15
20150174090 

Immune tolerance inducer


An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ala) or a derivative thereof, or a salt of the 5-ala or the derivative and an iron compound as active ingredients is prepared.
National Center For Child Health And Development


06/25/15
20150174063 

Oral administration of tocilizumab treatment of autoimmune disease


The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of tocilizumab.. .

06/18/15
20150166658 

Bcr-complex-specific antibodies and methods of using same


This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.


06/18/15
20150165006 

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen


The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Cure Gmbh


06/18/15
20150164902 

Concentrated methotrexate solutions


Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh


06/18/15
20150164800 

Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine


The present disclosure provides methods for modulating the interaction between a tam ligand and a lipid membrane containing phosphatidyl serine (ptdser). In one example, such methods use a tam receptor agonist having a ptdser-containing lipid bilayer membrane with gas6 and/or protein s bound to the membrane to activate signaling from one or more tam receptors and treat an autoimmune disease.
Salk Institute For Biological Studies


06/11/15
20150158912 

Treatment of il-17 mediated disease by blocking sefir-sefir interactions


A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.
The Cleveland Clinic Foundation


06/11/15
20150158871 

Crystalline forms of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics, Inc.


06/11/15
20150158865 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics, Inc.


06/11/15
20150158847 

Tropomyosin-related kinase (trk) inhibitors


Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation


06/04/15
20150152097 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


06/04/15
20150150969 

Chimeric and humanized anti-histone antibodies


The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.


06/04/15
20150150956 

Epitope composition


A pharmaceutical composition for sublingual, buccal or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.. .
Biotech Tools S.a.


06/04/15
20150150951 

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity


The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.

06/04/15
20150150912 

Ceacam1 mediated protective immunity


The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the ceacam1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue..

06/04/15
20150150869 

Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives


The present invention relates to compositions and methods for cancer treatment comprising compounds of formulae i, ii, and iii. In some aspects, the invention relates to the treatment of b-cell lymphoma or other hematopoietic cancers.
Eutropics Pharmaceuticals, Inc.


05/28/15
20150148413 

Desferrioxamine-metal complexes for the treatment of immune-related disorders


The present invention relates to methods kits and combined compositions using dfo-metal complexes, specifically, zinc-desferrioxamine (zn-dfo), gallium-desferrioxamine (ga-dfo) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.. .
Hadasit Medical Research Services And Development Ltd.


05/28/15
20150148361 

Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.. .
Janssen Pharmaceutica Nv


05/28/15
20150148360 

3,5,n-trihydroxy-alkanamide and derivatives: making same and use thereof


The present invention provides novel compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are inhibitors of histone deacetylases (hdacs) and 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase (hmgr).
National Taiwan University


05/28/15
20150148331 

Melt-extruded solid dispersions containing an apoptosis-inducing agent


A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a bcl-2 family protein inhibitory compound of formula i as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of formula i, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein.
Abbvie Deutschland Gmbh & Co Kg


05/21/15
20150141523 

Compounds for use in the treatment of autoimmune inflammatory disease


And salts thereof is useful in the prophylaxis or treatment of inflammatory bowel disease or other inflammatory autoimmune diseases with similar aetiology involving t-cell proliferation or or function.. .

05/21/15
20150141414 

Formulation of stable recombinant alpha-fetoprotein conjugated with anti-tumor substance in target-delivery system for treatment of cancer and autoimmune disease


Disclosed is a stable formulation based on rafp conjugated with drug delivery system of various classes of pharmacological agents such as dactinomycin, cardionolide, and bufadinolide, among others. In another embodiment, the invention discloses a method of producing rafp in a strain of methylotrophic pichia pastoris yeast, allowing the yeast to replicate, and extracting the newly created rafp.
Legrand International Llc


05/21/15
20150141397 

Substituted anilines as ccr(4) antagonists


Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.


05/21/15
20150141328 

Stimulation of human meibomian gland function


Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a pld-inducing compound, such as the cationic amphiphilic drugs (e.g. Azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, igf-1 or an igf-1 analogue (e.g.
The Schepens Eye Research Institute


05/21/15
20150140085 

Formulations comprising ibrutinib


Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.. .
Principia Biopharma Inc.


05/14/15
20150133457 

Heterocyclic compounds and uses thereof


The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, egfr (including her), alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, btk, or jak, and the respective pathways.. .

05/14/15
20150133450 

Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives


The present invention relates to compositions and methods for cancer treatment comprising compounds of formulae i, ii, and iii. In some aspects, the invention relates to the treatment of b-cell lymphoma or other hematopoietic cancers.

05/14/15
20150132788 

Establishing the viability of biological samples


The invention relates to a method, a use and a kit for establishing the viability (ability to live) of biological samples using ageladine a. The invention is advantageously suitable for establishing the viability of biological samples which can otherwise be dyed in an intra-cellular manner by fluorescence dyes other than ageladine a not at all or only with difficulty.

05/14/15
20150132369 

Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof


A liposomal formulation for targeting immunotherapy, with synergistic effect in the case of encapsulating an immunosuppressive drug, such as cyclosporine a, and the method of preparing the same. The reduced toxicity and significant reduction of delayed-type hypersensitivity dth) due to extremely reduced dosage, potential therapeutic value in control of chronic transplant rejection, allergies and certain autoimmune diseases, and increased efficacy are some of numerous and significant benefits of the present invention..

05/14/15
20150132326 

Immunosuppressive blood cells and methods of producing the same


The present invention refers to a method of producing immunosuppressive blood cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.. .

05/14/15
20150132312 

Systems and methods for extracorporeal blood modification


The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject.

05/14/15
20150132302 

Vaccine and uses thereof


The present disclosure provides immunogenic compositions, such as vaccines, including dna vaccines, and uses thereof, e.g., to suppress or prevent an immune response and/or to treat or prevent an autoimmune disease.. .

05/07/15
20150126488 

Nitrogen-containing bicyclic aromatic heterocyclic compound


[means for solution] it was found that a nitrogen-containing bicyclic heterocyclic compound has the excellent cathepsin s inhibitory effect, thereby completing the invention. The compound of the present invention has the cathepsin s inhibitory effect, and can be used as an agent for preventing and/or treating autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like..

05/07/15
20150125880 

Methods for induction of antigen-specific regulatory t cells


The present invention relates to methods to elicit immature antigen-presenting cells loaded with apoptotic cells or apoptotic bodies. The present invention also relates to methods of obtaining antigen-specific regulatory t cells in vitro or in vivo.
Katholieke Universiteit Leuven


05/07/15
20150125536 

Methods and compositions for sustained immunotherapy


This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of tr1 cells and/or breg cells in an antigen-specific manner and treating autoimmune diseases and disorders in a subject in need thereof.. .
Uti Limited Partnership


05/07/15
20150125514 

Biomarker


A method of diagnosis, prognosis or treatment of an autoimmune disease in a subject wherein the method comprises detecting aquaporin-1 (aqp1), aquaporin-2 (aqp2), aquaporin-5 (aqp5), aquaporin-7 (aqp7) and/or aquaporin-8 (aqp8) autoantibodies in a sample obtained from said subject.. .

05/07/15
20150125460 

Anti-bcma antibodies


This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases..
Biogen Idec Ma Inc.


05/07/15
20150125450 

Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease


The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex.
Ibc Pharmaceuticals, Inc.


05/07/15
20150125390 

18f-labelled folate/antifolate analogues


The present invention is directed towards new 18f-folate/antifolate analogue radiopharmaceuticals, wherein the phenyl group within folate structures has been replaced by an 18f-heterocycle, their precursors, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie




Popular terms: [SEARCH]

Autoimmune Disease topics: Autoimmune Disease, Immune Disease, Autoimmune, Autoimmune Diseases, Immune Diseases, Transplant, Infectious Disease, Infectious, Inflammatory Disease, Antagonist, Rheumatoid Arthritis, Proliferative, Nucleotide, Antibodies, Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.5296

5655

0 - 1 - 104